top of page

HNCIG-4/DE-ESCALATE RESULTS PUBLISHED IN LANCET

January 5, 2019


On this phase III trial, patients with low-risk oropharyngeal cancer were assigned to receive standard cisplatin-based CRT or radiotherapy plus cetuximab. Compared with the standard of care regimen, cetuximab showed no toxicity benefit, and negatively impacted tumor control. https://pubmed.ncbi.nlm.nih.gov/30449623/

3 views

Recent Posts

See All
bottom of page